Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.

@article{Goldstein2015NecitumumabIM,
  title={Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.},
  author={Daniel A Goldstein and Qiushi Chen and Turgay Ayer and David H Howard and Joseph B. Lipscomb and Suresh S Ramalingam and Fadlo R. Khuri and Christopher R Flowers},
  journal={JAMA oncology},
  year={2015},
  volume={1 9},
  pages={
          1293-300
        }
}
IMPORTANCE The SQUIRE trial demonstrated that adding necitumumab to chemotherapy for patients with metastatic squamous cell lung cancer (mSqCLC) increased median overall survival by 1.6 months (hazard ratio, 0.84). However, the costs and value associated with this intervention remains unclear. Value-based pricing links the price of a drug to the benefit that it provides and is a novel method to establish prices for new treatments. OBJECTIVE To evaluate the range of drug costs for which adding… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Necitumumab for the treatment of squamous cell non-small cell lung cancer.

  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2018
VIEW 12 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Cancer statistics ,

J Lortet-Tieulent, I Soerjomataram, +3 authors F Bray
  • 2015

Cancer: Unpronounceable Drugs, Incomprehensible Prices. http://www.forbes.com /sites/matthewherper/2014/08/13/cancer -unpronounceable-drugs-incomprehensible-prices

P. Bach
  • Accessed July
  • 2015